PharmaEssentia announces milestone in development of new third-generation interferon hepatitis B and C drug candidate
Release issued 18th June 2008
18 June, 2008, TAIPEI, Taiwan – Drug development company PharmaEssentia Corp. today announced that new PK/PD data on P1101, its third-generation PEG-interferon-alpha drug candidate for hepatitis B and C, showed the drug is particularly long-lasting compared to the two other pegylated-interferon drugs currently on the market. This indicates that PharmaEssentia's drug may only need to be injected once every two or more weeks by the patient, compared to the usual once-a-week administration.
Reducing dosage frequency is considered desirable for minimizing side effects and increasing the efficacy; and is more convenient for the patient as such biopharmaceutical drugs must usually be administered by injection.
Additionally, the modified structure of PharmaEssentia's PEG-INF-alpha makes for a purer drug, leading to a simpler manufacturing process and better quality control over the end product, particularly when produced at higher doses. P1101 has only a predominant single positional isomer connecting the PEG molecule on the protein, compared with 8 to 14 isomers found in the two other pegylated-interferon drugs, respectively.
Less frequent dosage should also mean a lower end cost and better compliance for the patient.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
You can read the full article by following the link currently on the front page of HepB.org